Fmr LLC Has $42.92 Million Position in Glaukos Corp (GKOS)

Fmr LLC boosted its holdings in Glaukos Corp (NYSE:GKOS) by 19.3% in the 2nd quarter, Holdings Channel reports. The firm owned 1,056,162 shares of the medical instruments supplier’s stock after buying an additional 171,092 shares during the quarter. Fmr LLC’s holdings in Glaukos were worth $42,923,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Swiss National Bank increased its stake in Glaukos by 7.1% during the first quarter. Swiss National Bank now owns 27,000 shares of the medical instruments supplier’s stock worth $832,000 after acquiring an additional 1,800 shares during the last quarter. Great West Life Assurance Co. Can increased its stake in Glaukos by 112.0% during the second quarter. Great West Life Assurance Co. Can now owns 4,240 shares of the medical instruments supplier’s stock worth $172,000 after acquiring an additional 2,240 shares during the last quarter. Principal Financial Group Inc. increased its stake in Glaukos by 10.2% during the first quarter. Principal Financial Group Inc. now owns 29,787 shares of the medical instruments supplier’s stock worth $918,000 after acquiring an additional 2,746 shares during the last quarter. State Board of Administration of Florida Retirement System increased its stake in Glaukos by 19.6% during the second quarter. State Board of Administration of Florida Retirement System now owns 18,773 shares of the medical instruments supplier’s stock worth $763,000 after acquiring an additional 3,070 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in Glaukos by 18.0% during the second quarter. Rhumbline Advisers now owns 32,001 shares of the medical instruments supplier’s stock worth $1,301,000 after acquiring an additional 4,884 shares during the last quarter.

Several equities research analysts have recently weighed in on GKOS shares. Stifel Nicolaus upped their target price on Glaukos from $32.00 to $35.00 and gave the stock a “hold” rating in a research report on Friday, August 3rd. Piper Jaffray Companies upped their target price on Glaukos to $46.00 and gave the stock an “overweight” rating in a research report on Friday, August 3rd. TheStreet raised Glaukos from a “d” rating to a “c-” rating in a research report on Monday, June 25th. Stephens reaffirmed an “overweight” rating and issued a $57.00 target price on shares of Glaukos in a research report on Wednesday, August 29th. Finally, JPMorgan Chase & Co. downgraded Glaukos from an “overweight” rating to a “neutral” rating in a research report on Thursday, June 21st. Three analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. Glaukos has an average rating of “Buy” and an average target price of $58.20.

In related news, Director Gilbert H. Kliman sold 502,760 shares of the stock in a transaction dated Thursday, August 30th. The stock was sold at an average price of $60.39, for a total value of $30,361,676.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Chris M. Calcaterra sold 38,983 shares of the stock in a transaction dated Thursday, August 2nd. The shares were sold at an average price of $44.44, for a total value of $1,732,404.52. Following the completion of the transaction, the chief operating officer now directly owns 278,983 shares of the company’s stock, valued at approximately $12,398,004.52. The disclosure for this sale can be found here. Insiders sold 691,743 shares of company stock valued at $37,911,081 in the last three months. 11.60% of the stock is currently owned by company insiders.

Shares of NYSE GKOS opened at $64.11 on Thursday. Glaukos Corp has a 1-year low of $23.08 and a 1-year high of $70.91. The stock has a market capitalization of $2.12 billion, a PE ratio of 1,214.40 and a beta of 1.46.

Glaukos (NYSE:GKOS) last issued its earnings results on Thursday, August 2nd. The medical instruments supplier reported ($0.15) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.03). Glaukos had a negative return on equity of 4.11% and a negative net margin of 3.49%. The company had revenue of $43.16 million during the quarter, compared to analysts’ expectations of $40.51 million. During the same period in the previous year, the company earned ($0.10) EPS. Glaukos’s quarterly revenue was up 4.5% on a year-over-year basis. research analysts expect that Glaukos Corp will post -0.55 EPS for the current fiscal year.

Glaukos Profile

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma.

See Also: What is Compound Annual Growth Rate (CAGR)?

Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corp (NYSE:GKOS).

Institutional Ownership by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply